SeeThruEquity Initiates Coverage on QuikFlo Health, Inc. (TSXV: QF) with a Price Target of CAD$1.25

NEW YORK, NY / ACCESSWIRE / January 29, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on QuikFlo Health, Inc. (TSXV: QF) with a Price Target of CAD$1.25.

The report is available here: QF Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

QuikFlo Health is based in Calgary, Canada and was co-founded by members of the thought-leading Calgary Stroke Program with the mission of developing artificial intelligence software to read CT scans and help doctors make better treatment decisions. QuikFlo’s flagship diagnostic tool, F.A.S.T. (Fast Accurate Stroke Triage), uses an algorithm modeled from the analysis of many thousands of CT scans to calculate the volume of brain affected by an active stroke, and the volume that is likely to die without treatment. QuikFlo plans to complete a working prototype of FAST during 2016E, and expects to be on the market in 2017.

“In our opinion, QuikFlo has assembled a world-class team to execute the remaining R&D, and to commercialize FAST successfully. QuikFlo’s potential to produce meaningful improvements in patient outcome give it a substantial chance to become a standard aspect of stroke triage workflows, and therefore a highly successful healthcare IT company,” stated Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of CAD$1.25 per share.”

Additional highlights from the report are as follows:

Large addressable market for stroke management products

Stroke is the leading cause of morbidity in the developed world, and one of the leading causes of mortality worlwide. The market for stroke management products, which is composed of diagnostic and therapeutic systems is expected to grow at a compound annual growth rate at 5.1%, as the prevelance of stroke doubles over the next 30 years.

The Problem with Stroke

The small- and mid-sized hospitals that comprise the vast majority of care centers worldwide lack internal expertise in stroke – on-staff stroke neurologists, neuroradiologists, and neuro-inverventionists – and routinely require help from outside experts to identify a stroke patients’ subtype and what treatment they should receive. The time that typically elapses between a patient’s CT scan, the reading of that scan, and the initiation of therapy is among the largest problems in stroke treatment, and accounts for much of the devastation of the disease. Reductions in this time interval are proven to significantly improve patient outcome.

Innovative F.A.S.T. technology

QuikFlo is developing a novel software, called FAST, that reads the CT scans of stroke patients to help first responders better understand that patient’s stroke subtype and initiate the appropriate treatment more independently. FAST uses an algorithm modeled from the analysis of many thousands of CT scans to calculate the terminal volume of brain that is currently affected by an active stroke, the volume that will die without treatment, and the amount that can be saved if the patient is referred for surgery (known as endovascular therapy, or EVT) immediately. This easy-to-digest output would enable far faster triaging of stroke patients, and a profound impact on their outcomes. It would also deliver significant cost savings to small and mid-sized hospitals, while driving increased revenue for large hospitals that can perform EVT.

Initiate coverage with a price target of $1.25

Our analysis indicates a fair value estimate of $1.25 per share implying an upside of 332.6% from the recent price of $0.29. We view QuikFlo Health as a speculative investment in the biotechnology industry with an innovative approach to develop an innovative solution for the analysis of medical images.

Please review important disclosures at www.seethruequity.com.

About QuikFlo Health, Inc.

QuikFlo Health is a Calgary-based software company that specializes in the development of innovative solutions for the analysis of medical images. QuikFlo has the exclusive rights to buy intellectual property that are being developed into an automated diagnostic tool, which interprets computerized tomography scans of stroke patients; thereby, providing specific treatment options to attending physicians. QuikFlo’s diagnostic tool has been developed at the University of Calgary and the University Stroke Center. QuikFlo’s mission is to provide cutting-edge stroke CT image analysis into a software that is fast, accurate, and easy for health professionals to use worldwide.

For more information, please visit the Company’s website at www.quikflohealth.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 436191